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Summary The advanced tumours of the digestive tract are generally less responsive to conventional
chemotherapies. Moreover, preliminary results with IL-2 immunotherapy also seem to show a low efficacy. On
the basis of our previous studies suggesting s synergistic action between IL-2 and some neurohormones, such
as the pineal indole MLT, a clinical trial was performed to investigate the clinical efficacy and tolerability of
an immunotherapy with IL-2 plus MLT in patients with advanced neoplasms of the digestive tract. The study
included 35 patients (colorectal cancer: 14; gastric cancer: 8; hepatocarcinoma: 6; pancreas adenocarcinoma:
7). Distant organ metastases were present in 31/35 patients. MLT was given orally at a daily dose of 50 mg at
8.00 p.m., starting 7 days before IL-2, which was given subcutaneously at a dose of 3 million IU/day at
8.00 p.m. for 6 days/week for 4 weeks, corresponding to one cycle of immunotherapy. In nonprogressed
patients, a second cycle was given after a 21-day rest period. A complete response was achieved in two patients
(gastric cancer: 1; hepatocarcinoma: 1). Six other patients obtained a partial response: (gastric cancer: 2;
hepatocarcinoma: 2; colon cancer: 1; pancreas cancer: 1). Therefore, the overall response rate was 8/35 (23%).
Stable disease was obtained in 11/35 (31%) patients, whereas the remaining 16 patients (46%) progressed. The
response rate was significantly higher in untreated patients than in those previously treated with
chemotherapy. Toxicity was low in all patients, who received the treatment as a home therapy.
This study shows that the immunotherapy with low-dose IL-2 plus the pineal hormone MLT is a new well
tolerated and effective therapy of advanced tumours of the digestive tract, mainly in gastric cancer and
hepatocarcinoma.
The real impact of chemotherapy on the survival time of
patients with advanced gastrointestinal tumours has still to
be established. Recently, some chemotherapeutic regimens,
such as cisplatin, 5-fluorouracil and epirubicin (Cunningham
et al., 1991), have been proven to be particularly effective in
gastric cancer. However, the important side-effects related to
the aggressive chemotherapies constitute detrimental factors
for the quality of life. These considerations justify the
elaboration of new therapeutic strategies of digestive tract
tumours, including endocrine and immune approaches. The
immunotherapy with interleukin-2 (IL-2) would represent
one of the most promising biological strategies, capable of
activating the antitumour immune response (Grimm et al.,
1982). At present, however, renal cell carcinoma and
melanoma seem to be the only neoplasms which have been
reported to respond to IL-2 immunotherapy (Rosenberg et
al., 1987), while most solid tumour histotypes have been
shown to be less responsive to IL-2. Several cytokines have
been used in association to enhance IL-2 efficacy, without,
however, any clear increase in IL-2 antitumour activity. The
recent investigations of the interactions between neuroendo-
crine and immune systems (Mathews et al., 1983; McCann et
al., 1987) have shown that several neurohormones may
modulate the immune responses, including IL-2-mediated
antitumour cytotoxicity. Within the neuroendocrine system,
the indole melatonin (MLT), which is released by the pineal
gland, has appeared to play an important immunomodulat-
ing role, either in animals (Maestroni et al., 1986) or in
humans (Lissoni et al., 1989). Therefore, another therapeutic
approach to enhance IL-2 antitumour activity could be repre-
sented by the concomitant administration of immunostimu-
lating neurohormones, such as MLT. Our preliminary
clinical studies have shown that MLT may improve the
immune status of metastatic cancer patients (Lissoni et al.,
1989) and to enhance the biological activity of IL-2 (Lissoni
et al., 1991) with a following decrease in the dose of IL-2
required to activate host biological response. Moreover, our
previous clinical trials have demonstrated that the association
between IL-2 and MLT may induce tumour regressions in
advanced non-small cell lung cancer, which is generally
nonresponsive to IL-2 alone (Rosenberg et al., 1987). On the
basis of these considerations, we have designed a clinical
study to evaluate the efficacy and the tolerability of the
association between IL-2 and MLT in patients with advanced
tumours of the digestive tract, which are generally less res-
ponsive to IL-2 alone (Dillman et al., 1991).
Materials and methods
The study included 35 consecutive patients with advanced
tumours of the digestive tract (M/F:22/13; median age 55
years, range 38-70), who were admitted to the Hospital of
Monza to receive IL-2 plus MLT as a first or second line
therapy for their advanced neoplastic disease. Nineteen
patients had been previously treated with chemotherapy,
whereas the other patients received the immunotherapy as a
first line treatment for their advanced disease. Eligibility
crtieria included: histologically proven cancer of the digestive
tract, no more than one previous chemotherapy, age less
than 75 years, Karnofsky's score greater than 30%. Patients
with brain metastases, double tumours or important car-
diovascular diseases were not included in the study. Histo-
type was colorectal carcinoma in 14, gastric carcinoma in
eight, adenocarcinoma of pancreas in seven, and hepatocar-
cinoma in six. Visceral lesions as dominant metastasis sites
were present in 31/35 patients, while the other four had a
locally advanced disease. The experimental protocol was
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explained to each patient, and informed consent was
obtained.
MLT was supplied by Medea Research (Milan, Italy).
Human recombinant IL-2 was supplied by Euro-Cetus (Am-
sterdam, Holland). MLT was given orally at a dose of
50mg/day in the evening (8.00 p.m.) because of its greater
biological activity in the night (Bartsch & Bartsch, 1981).
MLT was given every day, starting 7 days before the first
IL-2 injection as an induction phase to enhance host
biological response to IL-2 (Lissoni et al., 1991). IL-2 was
injected subcutaneously at 3 million IU/day at 8.00 p.m. for 6
days/week for 4 consecutive weeks, corresponding to one
cycle of therapy. We decided to administer IL-2 sub-
cutaneously because of its lower toxicity in comparison to the
intravenous route of administration (Atzpodien et al., 1991).
Moreover, we decided to give IL-2 in the evening because of
the spontaneous increase in lymphocyte proliferative capacity
in this period of the day (Ritchie et al., 1983). In non-
progressed patients, a second cycle was given after a rest
period of 3 weeks, after that patients followed a maintenance
period consisting of 1 week of therapy every month until
progression.
Radiological examinations were repeated after each cycle
of therapy, then every 2 months. Liver involvement was
investigated by CT scan. Clinical response and toxicity were
evaluated according to WHO criteria. Complete response
(CR) was a complete resolution of all clinically evaluable
disease for at least 1 month; partial response (PR) was
defined as at least 50% reduction in the sum of the products
of the longest perpendicular diameters of measurable lesions
for at least 1 month; stable disease (SD) was defined as no
objective tumour regression or increase greater than 25%;
progressive disease (PD) was defined as at least 25% increase
in measurable lesions or the appearance of new lesions.
Patients were considered as evaluable when they received at
least one complete cycle of therapy.
Routine laboratory tests, including leukocyte count, and
electrocardiogram were made before and repeated weekly
during IL-2 administration. Moreover, to analyse macro-
phage activation, serum levels of neopterin were also
measured at 1-week intervals, by using the RIA method and
commercially available kits (Henning, Berlin-Germany).
Data were statistically evaluated by the Student's t-test,
analysis of variance according to Newman Keuls test
adjusted for a correction factor, and chi-square test.
Results
Clinical data and response to therapy are reported in Table I.
Two patients achieved a CR, the former affected by gastric
cancer with liver metastases and the latter by locally
advanced hepatocarcinoma (duration: 19+ and 12+ months,
respectively). A PR was obtained in six other patients (gastric
cancer: 2; hepatocarcinoma: 2; colon cancer: 1; cancer of
pancreas: 1). Therefore, the objective tumour regression rate
was 8/35 (23%) patients. The objective regression rate was
significantly higher in untreated patients than in those
Table I Clinical data and response to therapy in 35 patients with advanced neoplasms of the digestive tract
treated with IL-2 plus MLT
Clinical response Response Progression sites
Duration Survival
Cases Sex Age Sites of disease Responsea Sites (months) (months)
Colorectal adenocarcinoma
bi F 42 Liver PD - Liver 4
b2 M 38 Peritoneum PR Peritoneum 3 Peritoneum 7
b3 F 69 Liver PD - - Liver 6
b4 M 63 Liver, lung PD - - Liver 5
b5 M 69 Liver, lung PD - - Brain 7
b6 F 43 Liver, lung PD - - Liver 4
b7 F 42 Liver, lung PD - - Liver 7
b8 F 40 Liver PD - - Liver 5
bg M 55 Peritoneum SD - 10 Peritoneum 14
blo M 50 Liver PD - - Liver 6
bI I F 65 Liver SD - 12+ - 12+
b12 M 69 Liver PD - - Liver 7
b13 M 55 Lung, bone, nodes SD - 5 Lung 12+
b14 M 58 Bone PD - - Bone 9
Gastric adenocarcinoma
bi M 56 Liver SD - 3 Liver 9
2 F 65 Liver CR Liver 19+ 19+
3 M 65 Liver PR Liver 4 Liver 7
4 M 70 Liver SD 9+ - 9+
b5 M 66 Liver SD 9+ 9+
b6 M 58 Liver, lung, bone PD - - Liver 2
7 M 49 Liver PR Liver 3+ 3+
8 M 62 Liver PD - - Liver 4
Hepatocarcinoma
1 M 54 Liver PR Liver 21+ - 21+
2 M 60 Liver, lung PD - - Liver 4
3 F 44 Liver CR Liver 12+ 12+
4 F 52 Liver, bone SD 6 Liver 7+
5 M 56 Liver, bone SD - 6+ 6+
6 F 54 Liver PR Liver 4+ 4+
Pancreas adenocarcinoma
1 M 61 Pancreas, liver SD - 3 Liver 4
2 F 52 Pancreas, liver SD - 6 Liver 8
b3 M 61 Pancreas, liver PD - - Liver 2
4 F 65 Pancreas, liver SD - 4 Liver 6
5 M 53 Pancreas PR Pancreas 4 - 4+
b6 F 48 Pancreas, liver PD - - Liver 5
7 M 64 Pancreas, liver PD - Pancreas 5
'CR = complete response; PR = partial response; s.d. = stable disease; PD= progressive disease. bPatients
pretreated with chemotherapy.1406 P. LISSONI et al.
Table II Clinical response to IL-2 plus MLT in relation to tumour histotype in 35
patients with advanced cancer of the digestive tract
Clinical response
Histotype n CR PR CR + PR s.d. PD
Overall patients 35 2 (6%) 6 (17%) 8 (23%) 11 (31%) 16 (46%)
Colon cancer 14 0 1 (7%) 1 (7%) 3 (21%) 10 (71%)
Gastric cancer 8 1 (13%) 2 (25%) 3 (37%) 3 (37%) 2 (25%)
Hepatocarcinoma 6 1 (17%) 2 (33%) 3 (50%) 2 (33%) 1 (17%)
Pancreas cancer 7 0 1 (14%) 1 (14%) 3 (43%) 3 (43%)
previously treated with chemotherapy (7/16 vs 1/19;
P<0.01). Eleven other patients (31%) obtained a s.d. (colon
cancer: 3; gastric cancer: 3; hepatocarcinoma: 2; cancer of
pancreas: 3). The remaining 16/35 (46%) patients rapidly
progressed. The mean survival time was significantly higher
in responder patients or in those with s.d. than in patients
who progressed under treatment (8.9 ± 1.1 vs 5.1 ± 0.5
months; P <0.05). Clinical response in relation to tumour
histotype is reported in Table II. All tumour regressions were
documented by CT scan.
Toxicity was low in all patients, and in particular no
cardiovascular, pulmonary, renal or haematological compli-
cations occurred. Fever higher than 38°C was observed in
only 6/35 (17%) patients, but it was limited to the first day of
IL-2 injection, which was made during the admission at the
hospital, after that patients followed IL-2 administration as a
home therapy. The only other side-effect was anorexia, which
occurred in 3/35 (8%) patients. On the contrary, a clear
improvement in the performance status was obtained in 9/35
(26%) patients.
Lymphocyte and eosinophil mean increase, as evaluated on
the first immunotherapeutic cycle, was significantly higher in
patients who responded or had a s.d. than in those progress-
ing under treatment as shown in Table III. On the contrary,
mean increase in serum levels of neopterin was significantly
higher in progressed patients than in those with response or
s.d. (6.8 ± 0.7 vs 2.6 ± 0.3 ngml-'; mean + s.e., P <0.01).
Table III Increase (mean ± s.e.) in lymphocyte and eosinophil
number (nmm-3) in relation to the clinical response to IL-2 plus
MLT in 35 patients with advanced tumours of the digestive tract
Patients n Lymphocytes Eosinophils
Patients with response 19 1690 ± 210a 1320 ± 1 loa
or stable disease
Progressed patients 16 690 80 540 ± 50
aP<0.01 vs progressed patients.
Discussion
This experimental clinical study shows that IL-2 at very low
doses is able to determine tumour progressions in advanced
neoplasms of the digestive tract when it is associated with the
pineal hormone MLT. Gastric cancer and hepatocarcinoma
would seem the gastrointestinal neoplasms more responsive
to the immunotherapy with IL-2 plus MT. Since IL-2 alone
is generally less effective in the treatment of gastrointestinal
tumours (Dillman et al., 1991), these results would suggest
that MLT may potentiate IL-2 antitumour activity in
humans, as previously observed in lung cancer (Lissoni et al.,
1992). The mechanisms by which MLT could synergise with
IL-2 have still to be better defined; however, they include at
least in part the modulation of suppresive events occurring
during the immunotherapy (Lissoni et al., 1991). In any case,
randomised clinical trials with IL-2 vs IL-2 plus MLT will be
required to define the real role of MLT as a possible agent to
extent the spectrum of IL-2 anti-tumour efficacy in humans.
As far as the relation between biological effects and clinical
response is concerned, this study would suggest that the
inhibitory control of tumour growth, obtained with IL-2 plus
MLT, is mediated by lymphocytes and eosinophils, whereas
the activation of macrophages, as documented by neopterin
increase, would negatively influence the efficacy of the
immunotherapy. This consideration is supported by the
evidence of a greater increase in lymphocyte and eosinophil
number and of a lower rise in neopterin levels in patients
with response or s.d. than in the progressed ones. The impor-
tance of host biological response in mediating the efficacy of
the immunotherapy is also suggested by the lower response
rate in patients previously treated with chemotherapy than in
the untreated ones. This finding could depend on chemo-
therapy-induced damage of bone marrow, which is the main
source of cytotoxic anticancer cells. Therefore, an eventual
immunotherapeutic treatment with IL-2 and MLT would
have to precede the chemotherapy in future possible
chemoimmunotherapeutic combinations of advanced neo-
plasms of the digestive tract.
In conclusion, this study shows that the immunotherapy
with low-dose IL-2 and the pineal hormone MLT may repre-
sent a new effective and well tolerated therapy of advanced
tumours of the digestive tract, apparently mainly in gastric
cancer and hepatocarcinoma.
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